We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Acadia Pharmaceuticals, a biopharmaceutical company utilizing innovative technology
to fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, announced that it has entered into a definitive purchase
agreement for a $36 million private placement of newly issued shares of common
stock and the concurrent issuance of warrants for the purchase of additional
shares of common stock.
Pfizer, Wyeth and Eli Lilly shareholders are being asked by pension funds to
take sides in the growing debate over importing cheaper drugs from Canada.
An Indiana startup company will commercialize a Purdue University treatment
for central nervous system injury and disease that has shown early promise in
bringing quality-of-life improvements to patients with paralysis.
Amphora Discovery Corp. has inked a two-year, multimillion dollar deal to buy
products used in the drug discovery process from Caliper Life Sciences Inc.
AXM Pharma announced that it has signed a $7.25 million distribution agreement
with Sinopharm Holding Guangzhou Co. Ltd for the company's line of Elegance,
Asarone and Anti-Fatigue products for distribution in Shanghai.
Memory Pharmaceuticals said on Friday its partner
Roche Holding AG will not continue developing two experimental Alzheimer's drugs
-- known as MEM 1414 and MEM 1917 -- on its own, and the two companies have begun
talks to determine the future of the compounds.
Responding to mounting fears about the safety of nonsteroidal anti-inflammatory
drugs (NSAIDs), the FDA recently announced a series of sweeping changes to the
entire drug class, including the withdrawal from the market of Pfizer's Cox-2
selective inhibitor Bextra.
The FTC has submitted a second request to Novartis Pharmaceuticals for additional
information about its pending acquisitions of German generic drugmaker Hexal
AG and U.S. generic firm Eon Labs.
The Centers for Medicare & Medicaid Services
(CMS) has placed its top medical officer on administrative leave for allegedly
falsifying documents and refusing to comply with a state medical board's investigation
into the matter.
The FTC has urged the FDA to reject a citizen petition from generic firm Ivax
Pharmaceuticals that seeks to have the agency relist patents on Merck's multibillion
dollar cholesterol drug Zocor, and not approve subsequent generic versions of
the product until Ivax's exclusivity period has expired.